Geode Capital Management LLC Purchases 62,555 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Geode Capital Management LLC boosted its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 8.1% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 835,790 shares of the company's stock after buying an additional 62,555 shares during the period. Geode Capital Management LLC owned 2.20% of Tarsus Pharmaceuticals worth $27,494,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the business. Quest Partners LLC purchased a new position in shares of Tarsus Pharmaceuticals in the second quarter worth $61,000. Canada Pension Plan Investment Board purchased a new stake in Tarsus Pharmaceuticals in the 2nd quarter worth $114,000. FMR LLC boosted its holdings in shares of Tarsus Pharmaceuticals by 236.6% during the 3rd quarter. FMR LLC now owns 5,032 shares of the company's stock valued at $166,000 after purchasing an additional 3,537 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Tarsus Pharmaceuticals by 33.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company's stock valued at $166,000 after purchasing an additional 1,530 shares during the last quarter. Finally, SG Americas Securities LLC grew its position in shares of Tarsus Pharmaceuticals by 87.5% during the third quarter. SG Americas Securities LLC now owns 7,242 shares of the company's stock valued at $238,000 after purchasing an additional 3,379 shares in the last quarter. Hedge funds and other institutional investors own 90.01% of the company's stock.

Tarsus Pharmaceuticals Trading Up 1.2 %

TARS stock traded up $0.65 during midday trading on Friday, reaching $55.00. 478,668 shares of the company traded hands, compared to its average volume of 706,881. The firm has a market capitalization of $2.10 billion, a price-to-earnings ratio of -14.44 and a beta of 1.04. Tarsus Pharmaceuticals, Inc. has a 52-week low of $18.99 and a 52-week high of $56.77. The business has a 50 day moving average of $48.24 and a 200-day moving average of $35.78. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on TARS shares. The Goldman Sachs Group boosted their target price on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a "neutral" rating in a research report on Friday, November 15th. Oppenheimer upped their price objective on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an "outperform" rating in a report on Thursday, November 14th. Finally, William Blair upgraded Tarsus Pharmaceuticals to a "strong-buy" rating in a research report on Friday, August 30th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Tarsus Pharmaceuticals presently has an average rating of "Buy" and a consensus target price of $54.20.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.